In this in-progress sequential multiple assignment randomized trial (SMART) 
designed to overcome the "one size fits all" approach to health care and identify treatments best suited for individuals (National Institutes of Health, 2015) . The National Institutes of Health (NIH) has encouraged use of novel research designs, such as the sequential multiple assignment randomized trial (SMART) , which includes sequences of treatments as opposed to single fixed treatments (Collins, Murphy, & Bierman, 2004 ).
The dynamic model of sequencing alternative treatments depending on observed success is ideally suited for the temporal and concurrent nature, and varying etiologies of multiple symptoms that present complex challenges to symptom management science (Kroenke, 2001 ).
The burden of symptoms resulting from cancer and its treatment contribute to diminished health related quality of life (HRQOL), as has been well-documented (Badger, Segrin, & Meek, 2011; Brant, 2016; Cleeland et al., 2013) . Existing static symptom management interventions deliver a predetermined dose at specific intervals and are tested against controls in standard randomized controlled trials (RCTs).
Although overall efficacy of an intervention may be established, heterogeneity may still exist in patient responses, and moderators of treatment outcomes may be identified that define groups of patients who benefit from interventions differentially (Kraemer, Wilson, Fairburn, & Agras, 2002; Sikorskii et al., 2015) . While the identification of moderators is one step toward accounting for heterogeneity, the next step of intervention sequencing and tailoring is needed to advance intervention science (Knobf et al., 2015) and the science of cancer symptom management in particular. In this SMART design approach, we rigorously test the adjustment of intervention type and/ or duration through sequencing that is based on patient response.
| METHODS

| Conceptual framework
Fatigue is the most prevalent and often distressing symptom related to cancer and its treatment (Armes, 2004) . The adapted Barsevick symptom management model (Barsevick et al., 2010) guides this study.
In this model, fatigue is defined through subjective experience of weariness, tiredness, and low energy, and objective experience through perceived impact on physical, cognitive, and psychosocial functioning. Improved management of fatigue (primary outcome) is the proposed mechanism for improving HRQOL. This improvement will be achieved by sequencing two evidence-based interventions in this trial.
| Overview of the SMART design
The SMART design of this study is summarized in Figure 1 and stems from over a decade of methodological research on multi-stage designs (Chakraborty, Murphy, & Strecher, 2010; Collins et al., 2004; Rush et al., 2003; Schneider et al., 2001; Thall, Millikan, & Sung, 2000; Wahed & Tsiatis, 2004) . For the first intervention stage, dyads (patients with solid tumor cancer and their caregivers) are randomized to 4 weeks of reflexology or meditative (mindfulness) practices provided by/with their caregiver in the patient's home or to a control group, with weekly assessments of patient symptoms (all groups) and intervention fidelity (intervention groups). For the dyads in which patients do not improve on fatigue (non-responders) based on 4 FIGURE 1 The SMART design weekly assessments, a 2nd randomization at 4 weeks is performed to either provide additional time with the single therapy during weeks 5-8, or to add the other therapy (reflexology or meditative practices, respectively) to facilitate patient symptom management. The weekly assessments of symptoms and intervention fidelity continue.
Adding the second therapy may result in better symptom management, or prove to be too intensive and burdensome for the dyad. This research will make this important determination and identify the best first-and second-stage therapies based on dyadic characteristics. The sustainability of these two evidence-based therapies and improvements in symptom outcomes are tested against controls during weeks 5-8 and at study week 12 in follow-up of 331 (postattrition) dyads.
| Specific aims and hypotheses
| Aim 1
To compare the reflexology and meditative practices groups in weeks 1-4 (first intervention stage) on the primary outcome of patient's fatigue severity and three secondary symptom outcomes: summed symptom severity index, depression, & anxiety, so as to determine: a) the relative effectiveness of these therapies; and b) the characteristics of patient responders and non-responders to each therapy.
Hypothesis 1
Patients randomized to the reflexology group will have lower fatigue severity, summed symptom severity index, depression, and anxiety at weeks 1-4, as compared to those randomized to meditative practices.
| Aim 2
Among patients who do not respond to reflexology with lowered fatigue severity during the first intervention stage, to determine the value added by meditative practices during weeks 5-8 (second intervention stage) versus continuing with reflexology alone for managing the fatigue severity and the three secondary symptom outcomes: summed severity index, depression, and anxiety.
Hypothesis 2
Patients who do not respond to reflexology with improvement in fatigue severity during weeks 1-4 (first intervention stage) and have the meditative practices added during weeks 5-8 (second intervention stage), will report lower fatigue severity and improvement on three secondary outcomes: summed severity index, depression, and anxiety, as compared to those who are re-randomized to continue with reflexology alone.
| Aim 3
Among patients who do not respond to meditative practices with lowered fatigue severity during the first intervention stage, to determine the value added by introducing reflexology during weeks 5-8 (second intervention stage) versus continuing with meditative practices alone for managing fatigue severity and the three secondary symptom outcomes: summed severity index, depression, and anxiety.
Hypothesis 3
Patients who do not respond to meditative practices with lowered fatigue severity during weeks 1-4 (first intervention stage) and have reflexology added during the second intervention stage (weeks 5-8), will report lower fatigue severity and improvement on three secondary outcomes: summed severity index, depression, and anxiety, as compared to those rerandomized to continue with meditative practices alone.
| Aim 4
To compare improvements in fatigue severity and the three secondary symptom outcomes among three groups created by the first randomization.
Hypothesis 4
Patients randomized to the respective intervention sequences will report lower fatigue severity and improvement on three secondary outcomes: summed symptom severity index at weeks 1-8 and week 12, depression and anxiety at week 12, compared to controls.
| Aim 5
To explore which dyadic characteristics observed during the first intervention stage are associated with optimal patient symptom outcomes during the second intervention stage (weeks 5-8) and at follow-up at week 12, so as to determine tailoring variables for the decision rules of sequencing future intervention stages.
| Sample
Patients are approached at the participating oncology clinics, which include two comprehensive cancer centers and three community oncology settings. Inclusion criteria are: 1) age 21 or older; 2) solid tumor cancer diagnosis; 3) able to perform basic activities of daily living; 4) undergoing chemotherapy, hormonal therapy, or targeted therapy; 5) reporting severity of >3 on fatigue using a 0-10 standardized scale at intake; 6) able to speak and understand English; 7) have telephone access; and 8) able to hear normal conversation. Exclusion criteria are: 1) diagnosis of major mental illness in medical record and verified by the recruiter; 2) nursing home resident; 3) bedridden; 4) currently involved with reflexology or meditative practices; or 5) presence of deep vein thrombosis or painful foot neuropathy.
Solid tumors were selected because fatigue is prevalent during their treatment (Sikorskii et al., 2007; Sikorskii, Given, You, Jeon, & Given, 2009; Wyatt, Sikorskii, Rahbar, Victorson, & You, 2012) .
Emerging evidence supports the potential efficacy of reflexology and meditative practices for fatigue management (Haller et al., 2017; Lehto, Wyatt, Sikorskii, Tesnjak, & Kaufman, 2015; . The cut-off of >3 indicates a moderate level of fatigue based on established interference-based cut-points (Given et al., 2008) . Virtually SIKORSKII ET AL. | 503 all patients with solid tumor cancer who are on chemotherapy will reach a threshold score of 2 or higher on fatigue at some point, and the cut-off score of 3 was found to be optimal in past work for balancing sensitivity and specificity in predicting needs for future symptom management .
A friend or family caregiver participates with each patient and completes a consent form. Caregiver inclusion criteria: 1) age 18 or older; 2) able to speak and understand English; 3) have access to a telephone; 4) able to hear normal conversation; and 5) willingness to be trained in reflexology and meditative practices.
| Sample size
The sample size determination started at the right end of the schematic in Figure 1 (the second randomization) and moved from right to left to determine the needed number of consenting patients. To power the comparisons for the value added by reflexology or meditative practices, the effect size of .45 was used, the smallest seen in preliminary work (Lehto et al., 2015; to conservatively estimate sample size requirements. The effect size of .45 corresponded to two repeated measures in past work, and the design of this study includes four repeated measures at each phase.
Assuming a correlation of .4 among repeated measures as seen in past work, the adjusted effect size for the longitudinal analysis of four time points is .54, which resulted in the sample size requirement of n = 55 per group being compared (far right of Figure 1 ), for power of .80 or greater in two-tailed tests at .05 level of significance. These 55 patients from four groups (220 total) created by the second randomization will be non-responders from the first intervention stage. Assuming that these 220 are 80% of the total number of patients in the first stage (i.e., that there is a 20% response rate to fatigue during the first 4 weeks), 276 patients needed to be randomized to interventions. The size of the control group was selected to be 55 to maximize power in the comparisons with intervention subgroups. Therefore, the total required post-attrition sample size is N = 331. To account for 23% attrition seen in symptom management trials with solid tumor cancers (Sikorskii et al., 2007; , 430 patients will need to provide consent.
Participants are assured of the confidentiality of all information and that refusing to participate will not alter their care. Patients will continue to receive standard medical care, so if any healthcare problems arise, they may seek care from their health providers. For patients who refuse to participate in the study, the recruiters seek consent to review their medical record for demographics and are asked the reason for refusal. These data contribute to external validity and generalizability of the findings.
| Procedures
| Recruitment
Recruiters at each site are trained by the study Education Coordinator; they have only research roles and do not provide direct patient care.
They approach patients during clinic visits and explain the study.
Patients can choose to consent at that time if their caregiver is present, or take the packet home to discuss with their caregiver. Recruiters follow up during a clinic visit or by phone to further explain the study, answer questions, and to discuss the study with caregivers. If verbal consent is obtained over the phone for the patient and/or caregiver, the consent forms in the packet are signed and returned in the stamped envelope provided.
| Randomization
Following the baseline interview, dyads are randomized to either reflexology, meditative practices or to the standard care control groups. Randomization is completed using a computer minimization algorithm (Taves, 1974) that balances arms by recruitment location, patient's site of cancer (breast, lung, colon, prostate, other), stage of cancer (early vs. late), and type of treatment (hormonal therapy alone vs. chemotherapy or targeted therapy with or without hormonal therapy). The second randomization occurs for those dyads in which patients do not respond on fatigue after the first 4 weeks of therapy.
The second randomization is implemented using the same approach as the first, with the same balancing factors, except that the randomization allocates dyads into two groups: continuing the same therapy or adding the other one during weeks 5-8.
| Interventions
Reflexology is similar to massage in that it manipulates soft tissue for therapeutic purposes, but differs due to the focus on the special areas of the feet called reflexes and the use of a firm thumb-walking motion (Watson & Voner, 2008) . It is based on the premise that foot reflexes correspond to organs, glands, and body systems. Stimulating these reflexes may positively affect function of the target tissue to facilitate health and healing (Watson & Voner, 2008) .
Meditative practices are purposeful strategies aimed towards building capacities to attend to the present moment, including one's thoughts, emotions, bodily sensations, and the environment with nonjudgmental openness and acceptance (Kabat-Zinn, 2009 ). This therapy selection is grounded in evidence that meditation training with gentle yoga and breathing exercises enhance patients' ability to adapt to serious medical concerns (Arch & Craske, 2006; Branstrom, Kvillemo, Brandberg, & Moskowitz, 2010; Carlson, Speca, Patel, & Goodey, 2004; Shapiro, Carlson, Astin, & Freedman, 2006; Tacon, Caldera, & Ronaghan, 2004) .
Caregivers are trained by a study reflexologist if a dyad is randomized to reflexology. For dyads randomized to meditative practices, both patient and caregiver are trained by a study meditation provider. After 4 weeks of delivering the therapy, training in the second therapy occurs based on results of re-randomization. The dyads can select the days of the week for the two therapies when randomized to receive both during weeks 5-8. Caregivers receive weekly calls over 8 weeks to maintain fidelity and inquire about the number of sessions completed in the past 7 days.
At least one weekly session is required per study procedures. The number of additional sessions per week is not restricted in a home- 
| Intervention fidelity
Intervention fidelity is assured through established methods outlined by the NIH Treatment Fidelity Workgroup to ensure consistency in dose, providers, delivery, receipt, and enactment of the intervention (Bellg et al., 2004) . Lead study trainers for reflexology and meditative practices providers will assure fidelity through maintenance of the procedural steps and delivery.
Dose consistency
Initially all patients randomized to intervention groups have 4 weeks of either reflexology or meditative practices with their caregiver. Weekly sessions for each of the two therapies are approximately 45-60 min long.
Provider consistency
All study providers pass a demonstration of >90% proficiency as judged by the lead trainers' score on the checklist for both therapies before beginning with caregivers. Caregivers must also achieve 90% accuracy.
Delivery consistency
There is a QA check and booster session conducted biannually for each study provider (those who teach caregivers one or both therapies), with a 90% proficiency required in delivery of the therapies. Caregivers are taught and evaluated during intervention weeks 1 and 2. If taught the second therapy after week 4, training and evaluation occurs again at weeks 5 and 6.
Receipt and enactment consistency
The Educational Coordinator calls every 7 days to ask the number of completed sessions since the last weekly call. A minimum of one session is required, with the exact number of sessions reported by the caregiver recorded weekly. Thus, fidelity of the receipt and enactment of each therapy is documented weekly over the 8-week intervention 
| Interviewer training
The interviewers call both members of the dyad at intake and at study week 12. Interviewers are blinded to the dyads' group assignments.
The Education Coordinator trains interviewers via didactic information, written steps, role-playing for difficult interview questions, and return-demonstrations based on study-specific criteria. In addition, 10% of all interviews are recorded for QA monitoring.
| Weekly calls to patients
The Education Coordinators make the weekly calls to all patients to assess symptoms during the 8-week intervention period, or an equivalent time frame for the control group. In this way, the attention of asking patients about their symptoms is equalized across groups.
When a symptom is rated at a 7 or higher on the 0-10 scale, patients are asked to contact their oncology office. For patients randomized to reflexology or meditative practices, data on the number of completed sessions are collected during these calls. Also, week 1-4 call data are used to assess response on fatigue for later randomization (see definition of symptom response below).
| Weekly calls to caregivers
The Education Coordinator calls the intervention caregiver every 7 days to assess the number of sessions conducted with the patient since the last call 7 days ago. During weeks 5-8, if re-randomized to add another therapy, the number of sessions is recorded for the initial and added therapy. The Education Coordinator makes these calls because interviewers need to be blinded to dyad group assignments. The cognitive component of fatigue is assessed with the 13-item AFI, which measures perceived effectiveness in essential daily challenges that require optimal cognition, and has shown consistent reliability in adults with breast cancer (Cimprich, 1992 , Cimprich, Visovatti, & Ronis, 2011 . In previous studies with lung cancer, alpha reliabilities were .89 and .91, respectively, (Lehto, 2013) .
| Measures
| Secondary symptom outcomes
Symptom Inventory (Cleeland, 2007) This instrument has established evidence of reliability and validity in samples of cancer patients (Cleeland et al., 2000) . It has been recently updated to include the most common symptoms experienced by patients undergoing modern cancer treatments (Cleeland et al., 2013) .
A single summed symptom severity score across 18 symptoms (without fatigue, because it is measured in more detail by the BFI and AFI as described above) is used as a secondary outcome in study Aims 1-4 and in building optimal decision rules in exploratory Aim 5.
However, during weekly calls to patients, the 19-symptom expanded MDASI (and not BFI or AFI) is used to efficiently collect symptom data.
Administration of the longer BFI would substantially increase respondent burden during 12 weekly calls.
The fatigue item from the MDASI is used for the determination of responders after week 4 due to the established cut-points with this measure. The available cut-points for mild, moderate, and severe fatigue needed to determine response to the intervention for week 4 re-randomization if necessary are based on a single-item fatigue rating (Given et al., 2008; Mendoza et al., 1999; Wang et al., 2014 ; see determination of response below). (Cella et al., 2010; PROMIS, 2012 PROMIS, , 2013a PROMIS, , 2013b ) (Patients; baseline and week 12)
PROMIS-Short Forms 4: Depression and Anxiety
These two symptoms are not directly covered by MDASI, which includes related items of distress and sadness. Therefore, the additional PROMIS measures for these symptoms are included (Cella et al., 2007 (Cella et al., , 2010 .
Testing in more than 21,000 individuals from the United States general population has resulted in individual item calibrations that produce tscores for the general population. The available short forms have evidence of reliability and validity. The four-item short forms were chosen to minimize respondent burden while maintaining measurement precision.
Determination of response on fatigue for re-randomization (Patients; weekly calls)
As mentioned previously, fatigue response is assessed with the fatigue item score from the MDASI administered in weekly calls.
Symptom onset is defined as the date of the weekly call when a symptom for the first time is reported by the patient as moderate or severe according to established and validated cut-points (Given et al., 2008) . The cut-points mark where the largest increases in symptom interference occur on a 1-10 severity scale, as severity increases between successive integers ranging from 1 to 10. Thus, the cut-points are anchored in symptom interference with patients' lives. For fatigue, the mild category corresponds to a severity score of 1, moderate category corresponds to scores 2-4, and scores of 5-10 fall into the severe category.
A cut-off score of 3 or higher on the inclusion criteria means that, at intake, all patients are experiencing fatigue at a moderate or severe level. Patients who started with a severe level of fatigue at onset and ended with moderate or mild levels by the 4-week observation, and patients who started at a moderate level and ended at mild, are called responders on fatigue ). Because responders demonstrate a substantial improvement anchored to fatigue interference with daily life after 4 weeks, they continue with the intervention for another 4 weeks. Patients who remain at moderate levels or move to severe at week 4 are classified as non-responders ). These patients are re-randomized to either continue with the same therapy, or add the second therapy, in order to rigorously test the value added by the second therapy in Aims 2 and 3. 
| Chronic conditions (Patients; baseline)
The Bayliss tool is used to query the presence of 20 comorbidities.
Patients can add co-morbid conditions that are not listed (Bayliss, Ellis, & Steiner, 2009 This tool incorporates items that assess perceived thoughts and feelings related to complementary therapy use. It has been modified to ask about the current therapy or therapies to which the dyad has been randomized. (Wyatt, 1993) (Patients; baseline & week 12) Determines the use of 24 therapies by patients.
| Complementary therapy utilization
2.10.6 | Caregiver Reaction Assessment Tool (Given et al., 1992) 
| Analytic methods
All data are entered into the secure web-based database. To maintain security, data are stored within a server different from the server of web application. Quarterly quality assurance checks of the data are performed. De-identified data will be transferred into SAS 9.4 for analyses.
Primary analysis outcomes are fatigue severity (primary, physical, and emotional from BFI, cognitive from AFI), summed severity index of other symptoms (secondary, from MDASI), depression (secondary, from PROMIS), and anxiety (secondary, from PROMIS).
| Baseline comparisons and regression techniques
The distributions of outcomes at baseline and potential covariates will be summarized. Outliers will be investigated by inspecting the residuals, and models described below will be fit with and without outliers to examine their influence on the results.
| Attrition analyses and handling of missing data
Dyadic characteristics will be compared for those who drop out between consent and first randomization to those who continue participation. Following the first randomization, attrition analyses will compare those who drop out according to the second randomization.
To inform the generalizability of findings, characteristics will also be compared for those who completed the study with those who did not within their designated group. The regression techniques described below allow for missing at random (MAR) mechanisms (Little & Rubin, 1987) . If patterns of missing data indicate potential not missing at SIKORSKII ET AL. | 507 random (NMAR) mechanisms, then models describing missing mechanisms will be considered (e.g., pattern-mixture models; Hogan, Roy, & Korkontzelou, 2004; Shen & Weissfeld, 2005) . Because NMAR or MAR assumptions are not directly testable, sensitivity analyses will be employed to investigate the robustness of the results under patternmixture or other models.
Aim 1, Hypothesis 1
Aim 1, Hypothesis 1 will be tested using statistical model #1 that relates the outcome y at weeks 1-4 to the group assignment variable (reflexology, meditative practices, or control), outcome at baseline, and variables used in randomization, due to their potential impact on outcomes. If errors are normally distributed, this model will be fit as a linear mixed effects model (LME), which generalizes classical analysis of repeated measures. Generalized linear mixed effects (GLME) modeling will be used with the appropriate link function and error distribution (e.g., gamma), if the symptom severity outcome is not normally distributed and cannot be normalized using transformations.
Primary interest is in the additive effect of the group variable, and differences in the least square (LS) means will be tested according to the levels of variable.
For Aim 1, part b, patients who are responders or non-responders will be defined as described above. The characteristics of responders and their caregivers will be compared to those of non-responders using t tests, chi-square, or Fisher's exact tests.
Aim 2, Hypothesis 2
The analytic strategy described under the analyses for Aim 1 will be implemented for the comparison of the two groups of reflexology nonresponders created by the second randomization. The repeated severity measures during weeks 5-8 and week 12 will be related to study group (reflexology alone vs. reflexology and meditative practices), symptom severity during week 4, and covariates. The test of the significance of the coefficient for the group variable will yield a formal test of Hypothesis 2 for the severity of fatigue and other symptoms. PROMIS measures of depression and anxiety obtained in the week 12 interview will be analyzed using general or generalized linear models, and the test of Hypothesis 2 for these two secondary outcomes will come from the significance of the coefficient for group assignment in the second randomization.
Aim 3, Hypothesis 3
The analysis for this aim is the same as the analysis for Aim 2, but will be performed among those who did not respond to meditative practices during weeks 1-4.
Aim 4, Hypothesis 4
The LME model described under analysis for Aim 1 will be extended to include eight repeated measures of symptom severity (from 8 weekly calls) and an additional measure from the week 12 interview. The test of significance of the explanatory variable reflecting the results of the first randomization will yield a formal test of Hypothesis 4. PROMIS depression and anxiety measures from the week 12 interview will be analyzed using generalized linear models with the following explanatory variables: group assignment at first randomization, depression or anxiety (respectively) at baseline, and balancing variables from the randomization.
Exploratory analysis: Aim 5
The analyses for this aim will help build optimal intervention sequences by determining the optimal decision rule specifying best first and second intervention stage. This determination is not as simple as determining the best intervention at a given stage while ignoring future interventions, which would ignore longer-term effects of the intervention that were inferior at stage 1 but produced better outcomes if simply continued versus combined with another intervention.
The analysis approach to this aim therefore follows the maximization method called Q-learning (Moodie, Richardson, & Stephens, 2007; Robbins, 2004) . The Q-learning algorithm proceeds from right to left in Figure 1 , that is, backwards from the last decision to the first. Two Q-functions will be considered. The function Q 2 H 2 ð Þ ¼ E½Y 2 jH 2 is the expectation of the second stage outcomeY 2 given history after 2 stages, denoted by H 2 : dyadic characteristics, outcomes observed during weeks 1-8 and week 12, and interventions received. and anxiety, and the optimal decision rule will be found using backward induction by maximizing these functions (Murphy, 2005; Sutton & Barto, 1998) . Given caregiver involvement in intervention delivery, caregiver characteristics including measures of symptoms (described in the section 2.9) will be explored, as the optimal decision rules may be based on both patient and caregiver factors.
The Q-learning method will be implemented in SAS PROC QLEARN ("PROC QLEARN (Version 1.0)", 2012) developed by Murphy (2003) . The procedure uses a generalization of Q-learning, which allows treatments and covariates to vary over time, a feature especially relevant to this trial that has weekly symptom assessments. Using this procedure, tailoring variables will be identified that can be used to operationalize the decision rules of selecting the first intervention and switching from the first intervention stage to the second. These decision rules can then undergo testing in a future confirmatory RCT.
| Human subjects protections
Institutional Review Board (IRB) approval was obtained at the investigators' University and participating sites.
2.12.1 | Security procedures for transfer, implementation, and storage of data 
| DISCUSSION
To date, in 1 year of recruitment, the study has enrolled 150 of the 430 dyads to be consented, with 3 years remaining. One of the challenges encountered during recruitment is the increasing availability at participating sites of integrative oncology services that include reflexology or meditative practices. Participants engaged in these therapies are ineligible for the trial. While the availability of such services helps improve patient care, these services often require travel to the clinic where they are offered. In contrast, this study offers reflexology and/or meditative practices in the patients' homes.
Also, recruitment of participants consisting of patient-caregiver dyads is more challenging than individual recruitment. The recruiters approach patients in the clinic but the friend or family caregiver often is not present with the patient. Many patients either do not have a caregiver or do not want to ask their caregiver to participate with them, due to perceived additional burden over what the caregiver is already doing for the patient. The team draws on past experience in addressing this issue (Holmstrom et al., 2015) . Once a contact with the caregiver is made, the refusal rate is low, and the caregivers agree to participate to increase their meaningful involvement in patient care. Researchers planning to enroll patient-caregiver dyads may think of ways to approach the caregiver not only through the patient but also through other avenues.
At least two of the four weekly contacts during weeks 1-4 are required for the determination of symptom response as a criterion for re-randomization, yet some patients skip some of the weeks. For those with one available weekly symptom assessment, severity of fatigue from the baseline interview is used as the initial time point in response determination. Those who do not complete any of the weekly calls during weeks 1-4 are considered drop-outs. The sample size of 430 allows for 23% attrition in order to maintain sufficient power to test study hypotheses.
To date, 40 dyads of 150 have been re-randomized. The rate of response of 20% was used for planning purposes in the sample determination, but currently, the response rate is somewhat greater for both therapies (33% for reflexology, and 24% for meditative practices). If this trend continues, the study may need to recruit more participants to have sufficient power to test Hypotheses 2 and 3 that involve non-responders to the first stage. Therefore in planning of future trials, using the most optimistic estimate for response rate would produce the most conservative sample size requirement.
Patients of all cancer stages are eligible for the study if they are receiving treatment at intake, and disease progression after consent does not preclude continued participation. In the team's past studies with late-stage breast cancer patients , many patients continued to participate even if they decided to stop treatment due to disease progression. Also, the team's extensive past experience with the two therapies, reflexology and meditative practices (Lehto et al., 2015; , ensures that caregivers are successfully trained in these therapies, and fidelity is maintained. The fidelity scorecard (Frambes et al., 2017) allows for quantitative evaluation of fidelity of the caregiver-delivered reflexology intervention. Similar tools can be developed for other therapies to support scientific rigor and reproducibility of study results.
In summary, the SMART design advances intervention science by optimizing individualized patient care for the best possible outcomes.
This design leads to decision rules for personalized symptom management that are consistent with precision medicine. Once tested in a future confirmatory trial, these decision rules will allow clinicians to implement the most useful therapy that based on a given patient's characteristics will reap the greatest benefit.
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